DGS Capital Management LLC Acquires 52 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DGS Capital Management LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 429 shares of the biopharmaceutical company’s stock after purchasing an additional 52 shares during the quarter. DGS Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $451,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Oddo BHF Asset Management Sas bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $1,598,000. American Trust acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $600,000. Synovus Financial Corp grew its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the third quarter. Synovus Financial Corp now owns 1,881 shares of the biopharmaceutical company’s stock worth $1,977,000 after purchasing an additional 61 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Regeneron Pharmaceuticals by 8.7% during the third quarter. Tidal Investments LLC now owns 6,350 shares of the biopharmaceutical company’s stock worth $6,675,000 after purchasing an additional 510 shares during the last quarter. Finally, Blankinship & Foster LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $2,081,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on REGN shares. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Citigroup initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 target price on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,099.90.

Regeneron Pharmaceuticals Trading Down 1.3 %

NASDAQ REGN opened at $731.30 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $728.68 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market cap of $80.36 billion, a P/E ratio of 18.10, a P/E/G ratio of 2.32 and a beta of 0.08. The stock’s 50-day moving average is $849.77 and its 200-day moving average is $1,003.80.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.